Abstract
Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient outcomes over the past 10 years. The pace of development of new targeted therapies is accelerating, with the associated need for molecular testing of new targetable alterations. As the complexity of biomarker testing in NSCLC increases, there is a need for guidance on how to manage the fluid standard-of-care in NSCLC, identify pragmatic molecular testing requirements, and optimize result reporting. An expert multidisciplinary working group with representation from medical oncology, pathology, and clinical genetics convened via virtual meetings to create consensus recommendations for testing of new targetable alterations in NSCLC. The importance of accurate and timely testing of all targetable alterations to optimize disease management using targeted therapies was emphasized by the working group. Therefore, the panel of experts recommends that all targetable alterations be tested reflexively at NSCLC diagnosis as part of a comprehensive panel, using methods that can detect all relevant targetable alterations. In addition, comprehensive biomarker testing should be performed at the request of the treating clinician upon development of resistance to targeted therapy. The expert multidisciplinary working group also made recommendations for reporting to improve clarity and ease of interpretation of results by treating clinicians and to accommodate the rapid evolution in clinical actionability of these alterations. Molecular testing of all targetable alterations in NSCLC is the key for treatment decision-making and access to new therapies. These consensus recommendations are intended as a guide to further optimize molecular testing of new targetable alterations.
| Original language | English |
|---|---|
| Pages (from-to) | 4981-4997 |
| Number of pages | 17 |
| Journal | Current Oncology |
| Volume | 29 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2022 |
Bibliographical note
Funding Information:D.N.I reports an institutional grant from Roche, honoraria from AstraZeneca, Pfizer, BMS, Roche, Merck, Amgen, Eli Lilly, and Bayer, support for attending meetings from Pfizer, participation in a stat safety monitoring board or advisory board from Astra Zeneca, Pfizer, BMS, Roche, Merck, Amgen, Eli Lilly, and Bayer, and a leadership/fiduciary role with Lung Cancer Canada. T.L.S. reports payment/honoraria for advisory boards from Janssen and Bristol Myers Squibb. S.B. reports institutional grants from AstraZeneca and Roche, consulting fees from Pfizer, Bayer, Novartis, and Janssen, and honoraria from Bayer and AstraZeneca. C.C. reports an ongoing institutional grant from Merck, ongoing payment/honoraria for presentations from AstraZeneca, and participation in a data safety board/advisory board at Institut d’Excellence en Santé et en Services Sociaux (INESSS) of the Ministère de la Santé et des Services Sociaux (MSSS) du Québec. C.A.M. reports consulting fees and payment/honoraria from Bayer Canada, Pfizer Canada, Eli Lilly, Merck Canada, and Roche Diagnostics. N.B. reports consulting fees from Amgen, AstraZeneca, Bayer, BeiGene, BMS, EMD Serono, Ipsen, Merck, Novartis, Pfizer, Roche, Sanofi, Servier, and Takeda. P.K.C. reports consulting fees from AstraZeneca, Bristol Myers Squibb, Amgen, Novartis, Pfizer, Merck, EMD Serono, BeiGene, Sanofi, Janssen, and Hoffman LaRoche, and payment/honoraria for presentations from Merck, Amgen, and BMS. Q.S-C.C. reports an institutional grant from AstraZeneca, consulting fees from AbbVie, Amgen, AnHeart, Astellas, AstraZeneca, BMS, BI, Eli Lilly, Jazz, Merck, Novartis, Pfizer, Roche, and Sanofi Takeda, honoraria from AstraZeneca and BMS, participation in a data safety monitoring board/advisory board with Merck KGaA, and an unpaid leadership/fiduciary role at Lung Cancer Canada. B.M. reports payment/honoraria for lectures/presentations from Merck, BMS, Roche, Novartis, AZ, Pfizer, and Janssen, support for attending meetings/travel from Pfizer, participation in a data safety board/advisory board from Merck, BMS, Roche, Novartis, AZ, Pfizer, and Janssen. N.B.L. reports institutional grants from Amgen, Array, Astra Zeneca, Bayer, BMS, Inivata, MSD, Novartis, Pfizer, Roche, Eli Lilly, EMD Serono, Guardant Health, and Takeda, honoraria for CME lectures from Amgen, BMS, GlaxoSmithKline, MSD, Novartis, Puma Biotechnology, Sanofi Genzyme, and Takeda, and participation on a data safety monitoring board or advisory board from Helsinn. All authors report honoraria from Janssen Canada for participation in the working group meetings, following which the submitted manuscript was drafted.
Funding Information:
Funding for the working group meeting was provided by Janssen Canada. The funder had no role in the development of the manuscript content. Janssen Canada provided funding for medical writing support through Precision Rx-Dx Inc. in accordance with version 3 of the Good Publication Practice guidelines (https://www.ismpp.org/gpp3 (accessed on: 21 November 2021).).
Publisher Copyright:
© 2022 by the authors.
ASJC Scopus Subject Areas
- Oncology
PubMed: MeSH publication types
- Journal Article
- Review
- Research Support, Non-U.S. Gov't
